Viracta Therapeutics closed NAVAL-1 trial for Nana-val in EBV+ lymphomas

From GlobeNewswire: 2024-12-26 16:30:00

Viracta Therapeutics, Inc. (Nasdaq: VIRX) is exploring strategic alternatives to maximize value, leading to the closure of its NAVAL-1 trial for Nana-val in EBV+ lymphomas. The decision aims to conserve resources during the review process. President and CEO Mark Rothera expressed gratitude to participants and staff. The company is in discussions for potential mergers, sales, or other transactions. No guarantees exist for agreements or timelines. Viracta focuses on virus-associated cancers with Nana-val, a combination therapy in clinical trials for lymphomas and solid tumors. Forward-looking statements caution on risks and uncertainties. Contact [email protected] for more information.



Read more at GlobeNewswire: Viracta Therapeutics Announces Closure of NAVAL-1 Clinical